call toll-free in North America 1.888.591.5577 outside North America call +1.604.456.6010
Response Biomedical Corporation
1781 - 75th Avenue W.
V6P 6P2 CANADA
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP® system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively.
In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
Response Biomedical is a publicly-traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
"I am very pleased to be leading Response Biomedical at this exciting time in the evolution of the Company. With partnerships in place with 3M Company, Roche Diagnostics and Shionogi & Co. Ltd., we are poised for strong growth. We also announced a new collaboration to develop a diagnostic for TB. We have begun working with FIND, a Bill and Melinda Gates-funded organization and we are excited about this and other future opportunities we continue to explore.
We are fortunate to be housed in a state-of-the-art manufacturing and product development facility. This global Headquarters will allow us to scale-up manufacturing to meet the needs of our current and future business partners and customers.
We have begun to see our major clinical tests launched into the marketplace by our partners. 3M launched the Flu A+B Test in October 2008 and Roche Diagnostics, the largest in vitro diagnostics company in the world, has now launched the cardiovascular line of products.
These are the building blocks which I believe will significantly enhance shareholder value while recognizing the extraordinary accomplishments of our Response Biomedical Team as a leader in the rapid point-of-care diagnostics marketplace."
S. Wayne Kay, CEO
Response Biomedical Obtains Special 510(k) U.S. FDA Clearance to Add Analytical Reactivity Information for the 2009 H1N1 Influenza A Virus to the RAMP® Influenza A/B Assay Package Insert
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has been granted a Special 510(k) U.S. FDA clearance for an update to the Company’s RAMP® Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens. The RAMP® Influenza A/B Assay is marketed in the United States by 3M Health Care as the 3M™ Rapid Detection Flu A+B Test and is used to identify influenza A and B in human specimens.
Although the RAMP® Influenza A/B Assay has been shown to detect the 2009 influenza A (H1N1) virus in cultured isolates, the performance characteristics of this device with clinical specimens that are positive for the 2009 influenza A (H1N1) virus have not been established. The RAMP® Influenza A/B Assay can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.
“We are very cognizant of physicians’ needs to quickly diagnose influenza and improve patient care in light of a potential influenza pandemic,” said S. Wayne Kay, Chief Executive Officer. “This clearance further validates our technology and combined with our recent RSV clearance will give 3M additional tools to promote the 3M™ Rapid Detection platform to hospitals, which help play a critical role in diagnosing and containing any upper respiratory infection outbreak.”
Response Biomedical Corporation Announced Second Quarter Results
Clinical Products Revenues Grow 373% over Q2 2008
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX:RBM) (OTCBB:RPBIF) reported that clinical products revenue for the three and six month periods ended June 30, 2009 increased 373% and 208% to $1,805,308 and $3,548,014, respectively, compared to $381,615 and $1,150,760 for the same periods in 2008. Total revenues for the second quarter increased 174% from the same quarter in 2008, from $997,515 in Q2/2008 to $2,735,415 in Q2/2009.
For the three and six month periods ended June 30, 2009, the Company reported a loss of $1,898,987 or $0.01 per share and $3,630,402 or $0.02 per share, respectively, compared to a loss of $3,740,494 or $0.03 per share and $7,284,605 or $0.05 per share for the same periods in 2008. This decrease in the loss for the three and six months period ended June 30, 2009 of 49% and 50%, respectively, is primarily due to higher gross profit on product sales, higher contract service fee and revenues from collaborative research arrangements and reduced expenses across all departments.
“We are continuing to show strong results as we work with our partners to introduce our rapid point-of-care (POC) diagnostic tests to an expanding market,” said S. Wayne Kay, CEO, Response Biomedical. “We had the second consecutive quarter with the highest revenues for any quarter in the Company’s history. These strong financial results for the first half of 2009 ensure we remain on track to finish the year with record revenues.”
The RAMP® System provides a quantitative measurement of cardiac markers in whole blood to assist in the diagnosis of a heart attack.
Each year in North America more than six million people go to emergency rooms with severe chest pain. Only 10% of those hospitalized suffer a heart attack, and approximately 40,000 are misdiagnosed and sent home rather than admitted for treatment.
The total cost of unnecessary admissions and misdiagnosis is approximately $4 billion a year, and the liability costs associated with this disease are the highest in the healthcare industry.
RAMP is easy-to-use, cost effective, and delivers reliable results in less than 15 minutes for most assays. This point-of-care (POC) method is considerably faster than traditional laboratory results, and faster turn around translates to improved patient outcomes and reduced hospital costs. Learn more about how the RAMP System works.
Results from independent multi-center US clinical trials of RAMP tests for Troponin I and CK-MB demonstrated significantly improved performance over the current market leading POC system, and excellent correlation of results with main lab instruments. Utilizing proven antibody-antigen complexes, state of the art fluorescence analysis, and economical lateral flow test strips, RAMP delivers highly sensitive results without compromising accuracy and cost.
High Sensitivity Flu A+B Test:
Response Biomedical has received FDA clearance to market a new high sensitivity rapid test for detecting Influenza A and B (Flu A+B). Initial results suggest the capability of producing highly sensitive and reliable information with significant performance improvements over established rapid immunoassays.
Due to the limited sensitivity of current rapid screening tests, there is a substantial market opportunity for a rapid high sensitivity flu test. Improved rapid screening will enable early detection, containment, and treatment of patients in a hospital or physician office setting. Response Biomedical anticipates its RAMP System will establish a new industry standard in rapid Flu A&B testing worldwide. Read More on Response Biomedical Receives U.S. FDA 510(k) Market Clearance of Rapid Influenza A+B Test
The test will be marketed and sold exclusively by 3M as the 3M Rapid Detection Influenza A+B test. Visit the US 3M Medical Diagnostics web site at www.howtocatchtheflu.com
The Flu Virus
Influenza (the flu) is a contagious disease that is caused by the influenza virus. It attacks the respiratory tract in humans (nose, throat, and lungs). The Three Types of Influenza Viruses are: Influenza A, B, and C. Influenza types A or B viruses cause epidemics of disease almost every winter.
During the influenza epidemics every year, an estimated half a million people die worldwide. In 2001, only 250 million vaccine doses were used globally, whereas the people at greatest risk of dying from influenza - those aged over 65 - already number more than 380 million¹.
RAMP Biodetection System Overview:
The RAMP® System is the new gold standard in biological field detection. RAMP provides first responders, military personnel and public safety workers, and those responsible for facility security with rapid, on-site, reliable information.
Independently evaluated, and AOAC approved, RAMP offers unmatched sensitivity and reliability. Tests are available for anthrax, ricin, bot tox and pox.
RAMP's 15 minute results leave other field tests far behind. No cross reactivity, no timing required, no standing and waiting for answers. See the RAMP Biodetection System in Action!
Designed for use in the field, RAMP combines the use of fluorescence with a proprietary Internal Standard that overcomes the performance limitations of early generation immunoassays. As a result, RAMP provides a level of sensitivity, specificity and reliability that is unprecedented in the area of rapid on-site biological detection.
Each RAMP purchased for use in North America includes on-site training performed by Emery & Associates, Inc., specialists in international emergency response consulting and training.
The RAMP System consists of a portable scanning fluorescence Reader and single-use, disposable test cartridges. To use, a small sample is added to the test cartridge and then inserted into the Reader. RAMP provides a positive or negative result in minutes.
The RAMP System has been relied upon by United Nations biological weapons inspectors in Iraq, and systems are used worldwide.
RAMP West Nile Virus Test
The RAMP® West Nile Virus (WNV) Test is a highly sensitive pre-screening test used for identifying WNV in mosquitoes and corvids. RAMP is used by public health laboratories, veterinary diagnostic laboratories, universities and mosquito control districts.
Why wait days for lab results? Save time by using RAMP for quick pre-screening. Now you can effectively manage your WNV program in a timely manner.
The RAMP WNV Test was independently validated by the US Center for Disease Control (CDC) and Canadian National Microbiology Lab (NML) to confirm:
- 80% in correlation to PCR
- 96% in correlation to ELISA
Easy to use
simple to use
, takes minutes to set up and results are easy to interpret. There is no calibration or maintenance required.
Learn more about how the RAMP System works
No manual recording of results. Up to 500 results can be stored in the RAMP reader memory and printed or uploaded to your computer. You can e-mail your data by saving it as a Microsoft excel file and sending as an attachment.
3 year weekly...
Response Biomedical Corp Stock Chart (RBM) TSE:RBM
Title : Response Biomedical Q3 Update
Date : Tuesday November 10th, 2009 at 10:00 AM ET
Response Biomedical Corp. engages in the research, development, commercialization, and distribution of diagnostic technologies for the medical point-of-care (POC) and on-site environmental testing markets. It provides a technology called Rapid Analyte Measurement Platform (RAMP), which is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. The company's RAMP tests are used in the early detection of heart attack, congestive heart failure, environmental detection of West Nile Virus, and biodefence applications, including the rapid onsite detection of anthrax, smallpox, ricin, and botulinum toxin.
Response Biomedical also develops and manufactures RAMP immunoassays for clinical, pharmaceutical, industrial, environmental, and agricultural applications. It has operations in Canada, the United States, and Asia. The company was founded in 1980 and is based in Burnaby, Canada.